logo
Share SHARE
FONT-SIZE Plus   Neg

E-Therapeutics Granted Approval For Phase I Trials Of Anti-cancer Drug ETS2101

Biotechnology company e-Therapeutics Plc (ETX.L) Thursday announced that its plans for Phase-1 trials of its anti-cancer drug ETS2101 have received approvals from the regulatory authorities both in the UK and in the US.

Following the receipt of approvals, the company reaffirmed that enrolment of patients for the Phase-1 trial in both the US and the UK would be commencing shortly.

Professor Malcolm Young, CEO of e-Therapeutics, said: "We remain on track to report the first data from cancer trials with ETS2101 and to advance three further drugs into the clinic by the end of this year."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
They say there's plenty of fish in the sea, but very few of them are as wealthy as these tycoons. May be they have been so busy building their empires they never had the time to stick with a perfect partner to build their family. This list of the richest singles is assorted — from a 34 year-old... Anthony Levandowski, the head of Uber's self-driving division, is stepping away from his role as Uber continues a legal battle with Waymo, Levandowski's former employer. Levandowski, who founded startup Otto, became head of Uber's Advanced Technologies Group or ATG after Otto was acquired by Uber in August 2016. Southwest Airlines Co. has decided to end the practice of overbooking flights, the airline's CEO Gary Kelly said Thursday. The airline's plan to end overbooking could be implemented from May 8, according to a Southwest spokeswoman.
comments powered by Disqus
Follow RTT